CureVac to start first mRNA prostate cancer vaccine trial Phase I

[Guest guest]

CureVac has announced that Germany¢s

regulatory authority has approved the firm¢s clinical trial application

to begin a Phase I study of its messenger ribonucleic acid (mRNA)

vaccine in patients with hormone-refractory metastatic prostate cancer. The

vaccine, CV9103, comprises modified long chain mRNA molecules coding

four different antigens expressed by prostate cancer cells. The Phase I

trial will be conducted in Germany and Italy and the Tuebingen-based

company said that initial results are expected by the third quarter of

next year. Click on the below link for the full story:<http://www.pharmatimes.com/WorldNews/article.aspx?id=14929>